Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07688304 · ClinicalTrials.gov registry record · NA
The Abuse Liability of IQOS Heated Tobacco Products Among Adults Who Smoke
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Not yet
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT07688304: Clinical Trial NA study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT07688304 is a NA study that has not yet begun recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07688304, a NA study, has not yet begun recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This clinical trial aims to evaluate user sensory experiences and smoking behavior when using IQOS heated tobacco products (HTPs) among adults who smoke cigarettes.
Primary Outcome
Participants will complete the Appeal and Sensory Quality questionnaire. This questionnaire will ask participants to rate each study product for appeal characteristics such as liking, willingness to use again, flavor intensity, pleasantness of taste, etc. on a scale of 0 (not at all) - 100 (extremely). Higher scores indicate greater liking, willingness to use again, flavor intensity, etc.
Interventions
- BEHAVIORAL Smoking Behavioral Research (IQOS)
- BEHAVIORAL Smoking Behavioral Research (UBC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-10 |
| Phase | NA |
What is known before NCT07688304 opens enrollment
NCT07688304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Smoking Behavioral Research (IQOS) is the first listed.
NCT07688304 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07688304 about?
NCT07688304 is a clinical study titled "The Abuse Liability of IQOS Heated Tobacco Products Among Adults Who Smoke". This clinical trial aims to evaluate user sensory experiences and smoking behavior when using IQOS heated tobacco products (HTPs) among adults who smoke cigarettes.
What is the current status of trial NCT07688304?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-07. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07688304?
The interventions under investigation include: Smoking Behavioral Research (IQOS) (BEHAVIORAL), Smoking Behavioral Research (UBC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07688304?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07688304's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia